Consistent with studies of Hodgkin lymphoma47, bladder cancer53, and glioblastoma78, our data suggest that CD4+ T cells, and particularly the PD-1+ CD4+ T cell subset, are crucial effectors that influence pembrolizumab response in CTCL. The gene discussed is CD4; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.